Department of Laboratory Medicine, The First Affiliated Hospital, Fujian Medical University, Fuzhou, People's Republic of China.
Clinical Laboratory Diagnostics, The First Clinical College, Fujian Medical University, Fuzhou, People's Republic of China.
Emerg Microbes Infect. 2022 Dec;11(1):2486-2501. doi: 10.1080/22221751.2022.2125344.
Hepatitis B virus (HBV) exists as quasispecies (QS). However, the evolutionary characteristics of haplotypes of HBV X gene in the hepatocellular carcinoma (HCC) microenvironment remain unclear. Mutations across X gene are essential for the tumorigenicity of HBV X protein (HBx). However, the functional phenotypes of many mutant HBx remain unknown. This study aims to compare the characteristics of X gene evolution between tumour and non-tumour tissues in HCC patients and investigate the tumorigenic phenotype of HBx harbouring mutation T81P/S101P/L123S. This study included 24 HCC patients. Molecular cloning of X gene was performed to analyse characteristics of haplotypes in liver tissues. HCC cell lines stably expressing wild-type or mutant HBx and subcutaneous tumour xenograft mouse model were used to assess HBx-T81P/S101P/L123S tumorigenicity. The mean heterogeneity of HBV QS across X gene in tumour tissues was lower than that in non-tumour tissues. A location bias was observed in X gene clones with genotype C or D in tumour tissues compared to those with genotype B. Mutations in genotype-C or - D clones were mainly clustered in the dimerization region and aa110-aa140 within the transactivation region. A novel mutation combination at residues 81, 101 and 123 was identified in tumour tissues. Further, HBx-T81P/S101P/L123S promotes cell proliferation and increases genomic instability, which was mediated by MYC. This study elucidates the compartmentalized evolution patterns of HBV X gene between intra tumour and non-tumour tissues in HCC patients and provides a new mechanism underlying HBV-driven hepatocarcinogenesis, suggesting a potential viral marker for monitoring HCC.
乙型肝炎病毒(HBV)存在准种(QS)。然而,HBV X 基因在肝癌(HCC)微环境中单体型的进化特征尚不清楚。X 基因的突变对于 HBV X 蛋白(HBx)的致瘤性至关重要。然而,许多突变 HBx 的功能表型仍然未知。本研究旨在比较 HCC 患者肿瘤和非肿瘤组织中 X 基因进化的特征,并研究携带突变 T81P/S101P/L123S 的 HBx 的致瘤表型。本研究纳入了 24 例 HCC 患者。对 X 基因进行分子克隆,分析肝组织中单体型的特征。使用稳定表达野生型或突变 HBx 的 HCC 细胞系和皮下肿瘤异种移植小鼠模型来评估 HBx-T81P/S101P/L123S 的致瘤性。肿瘤组织中 X 基因 QS 的平均异质性低于非肿瘤组织。与基因型 B 相比,基因型 C 或 D 的肿瘤组织中 X 基因克隆存在位置偏倚。基因型-C 或 -D 克隆中的突变主要聚集在二聚化区域和反式激活区的 aa110-aa140 内。在肿瘤组织中发现了新的突变组合,位于残基 81、101 和 123 处。进一步的研究表明,HBx-T81P/S101P/L123S 促进细胞增殖并增加基因组不稳定性,这是由 MYC 介导的。本研究阐明了 HCC 患者肿瘤内和非肿瘤组织中 HBV X 基因的分隔进化模式,并为 HBV 驱动的肝癌发生提供了新的机制,提示了一种用于监测 HCC 的潜在病毒标志物。